文献速递肾小球疾病

COVID-19疫苗接种与肾小球肾炎

COVID-19 Vaccination and Glomerulonephritis.
PubMed 文献 · Kidney Int Rep · 2021-10-06

该病例系列评估了13例患者在mRNA COVID-19疫苗接种后新发或复发肾小球肾炎(GN)的情况。中位年龄62岁,IgA肾病最常见(38%),77%发生急性肾损伤(AKI),80%对治疗有反应。结论认为GN可在接种后短期内出现,新发IgA肾病可能源于免疫激活揭露出未诊断的IgA肾病。

要点

  • mRNA疫苗接种后新发或复发GN以IgA肾病最常见。
  • 多数患者出现AKI,但总体治疗反应良好。
  • 新发IgA肾病可能为免疫激活揭露既存沉积。

核心结论

  • mRNA COVID-19疫苗接种后短期内可出现GN新发或复发,新发IgA肾病可能源于免疫激活揭露未诊断的IgA肾病而非新沉积形成。

研究设计与样本

  • 单中心病例系列,纳入13例接种mRNA COVID-19疫苗后新诊断或复发GN的患者,评估基线特征、疫苗类型和临床结局。

主要发现

  • 13例中8例新诊断GN,5例复发;中位年龄62岁(范围19-83岁)。
  • 最常见基础疾病为自身免疫病(38%),其次为癌症(23%);多数为白人男性。
  • IgA肾病最常见(5例,38%),其次为膜性肾病(3例,23%)。
  • 77%发生AKI,其中多数为KDIGO 1期(67%);80%对治疗有反应。
  • 包含首例tip变异型FSGS、NELL-1相关膜性肾病和非典型抗GBM肾炎的病例报告。

临床怎么用

  • 接种mRNA COVID-19疫苗后短期内出现血尿、蛋白尿或肾功能下降时,应警惕GN新发或复发。

局限性

  • 样本量小(13例),为单中心病例系列,无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: mRNA COVID-19 vaccine is more effective than traditional vaccines owing to superior immune activation. Nevertheless, the impact of mRNA COVID-19 vaccine on triggering de novo/relapsing glomerulonephritis (GN) is limited. We report a case series of patients who developed new or relapsing GN postvaccination. METHODS: We evaluated baseline characteristics, vaccine type, and clinical outcomes of 13 patients from our institution who had a new diagnosis or relapse of their GN post-mRNA COVID-19 vaccination. RESULTS: Of 13 patients, 8 patients were newly diagnosed with having GN and 5 patients had relapse. Median age was 62 years (range 19-83 years). Autoimmune disease (38%) was the most prevalent underlying disease followed by cancer (23%). Most patients were White males. IgA nephropathy (IgAN) was the most common GN in our series (5 patients, 38%) followed by membranous nephropathy (MN) (3 patients, 23%). There was 1 patient with IgAN who had evidence of IgA deposits before vaccination suggesting the immune activation after vaccination triggered a flare of the disease. Our case series also included the first case report of tip-variant focal segmental glomerulosclerosis (FSGS), NELL-1-associated MN, and atypical anti-glomerular basement membrane (GBM) nephritis. A total of 77% developed acute kidney injury (AKI) with most being Kidney Disease: Improving Global Outcomes stage 1 (67%). Outcomes are favorable with 80% responding to therapy. CONCLUSION: New cases and relapse of GN can present shortly after mRNA COVID-19 vaccination. New cases of IgAN may result from unmasking of undiagnosed IgAN owing to robust immune activation rather than development of new deposits.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Klomjit N, Alexander MP, Fervenza FC, et al. COVID-19 Vaccination and Glomerulonephritis. Kidney Int Rep. 2021. PMID: 34632166. doi:10.1016/j.ekir.2021.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。